Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Uno studio sull'ustekinumab nei partecipanti pediatrici con malattia di Crohn da moderatamente a gravemente attiva (UNITI Jr)

2 luglio 2026 aggiornato da: Janssen Research & Development, LLC

Uno studio di fase 3 sull'efficacia, la sicurezza e la farmacocinetica di ustekinumab come trattamento di induzione endovenosa in aperto seguito da mantenimento di ustekinumab sottocutaneo randomizzato in doppio cieco in partecipanti pediatrici con malattia di Crohn da moderatamente a gravemente attiva

Lo scopo di questo studio è valutare l'efficacia del dosaggio di ustekinumab nell'indurre la remissione clinica (globale) e nel mantenere la remissione clinica (US); valutare il profilo di sicurezza e l'esposizione a ustekinumab (farmacocinetica [PK]) nei partecipanti pediatrici con malattia di Crohn da moderatamente a gravemente attiva.

Panoramica dello studio

Stato

Completato

Condizioni

Intervento / Trattamento

Tipo di studio

Interventistico

Iscrizione (Effettivo)

101

Fase

  • Fase 3

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Luoghi di studio

      • Brussels, Belgio, 1200
        • Cliniques Universitaires Saint Luc
      • Brussels, Belgio, 1020
        • Universitair Kinderziekenhuis Koningin Fabiola
      • Ghent, Belgio, 9000
        • UZ Gent
      • Jette, Belgio, 1090
        • UZ Brussel
      • Leuven, Belgio, 3000
        • UZ Leuven
      • Aachen, Germania, 52074
        • Universitätsklinikum Aachen
      • Berlin, Germania, 13353
        • Charite-Universitätsmedizin Berlin - Berlin
      • Essen, Germania, 45147
        • Universitätsklinikum Essen
      • Hanover, Germania, 30625
        • Medizinische Hochschule Hannover
      • Munich, Germania, 80337
        • Dr. von Haunersches Kinderspital
      • Regensburg, Germania, 93049
        • KUNO Klinik St. Hedwig
      • Ulm, Germania, 89075
        • Universitätsklinikum Ulm
      • Bunkyō City, Giappone, 113 8431
        • Juntendo University Hospital
      • Gunma, Giappone, 371-0034
        • Gunma University Hospital
      • Ikoma, Giappone, 630-0293
        • Kindai University Nara Hospital
      • Kurume, Giappone, 830-0011
        • Kurume University Hospital
      • Saitama Shi, Giappone, 330-8777
        • Saitama Childrens Medical Center
      • Sendai, Giappone, 989-3126
        • Miyagi Children's Hospital
      • Setagaya Ku, Giappone, 157 8535
        • National Center for Child Health and Development
      • Shimotsuke, Giappone, 329-0498
        • Jichi Medical University Hospital
      • Tsu, Giappone, 514 8507
        • Mie University Hospital
      • Be’er Ya‘aqov, Israele, 70300
        • Yitzhak Shamir Medical Center
      • Haifa, Israele, 34362
        • Carmel Medical Center
      • Jerusalem, Israele, 9103102
        • Shaare Zedek Medical Center
      • Petah Tikva, Israele, 4920235
        • Schneider Children's Medical Center
      • Gdansk, Polonia, 80 803
        • Szpital im. M. Kopernika
      • Krakow, Polonia, 30 663
        • Uniwersytecki Szpital Dzieciecy w Krakowie
      • Rzeszów, Polonia, 35-302
        • Korczowski Bartosz Gabinet Lekarski
      • Warsaw, Polonia, 04 501
        • WIP Warsaw IBD Point Profesor Kierkus
      • Warsaw, Polonia, 04 730
        • Instytut Pomnik Centrum Zdrowia Dziecka
      • Birmingham, Regno Unito, B4 6NH
        • Birmingham Children's Hospital
      • Bristol, Regno Unito, BS2 8BJ
        • University Hospitals Bristol and Weston NHS Foundation Trust
      • Cambridge, Regno Unito, CB2 0QQ
        • Cambridge University Hospitals NHS Foundation Trust
      • Edinburgh, Regno Unito, EH16 4TJ
        • Royal Hospital for Children and Young People
      • London, Regno Unito, E1 2AT
        • Royal London Hospital
      • Kazan', Russia, 420138
        • Kazan State Medical University
      • Moscow, Russia, 119571
        • Russian National Research Medical University named after N.I.Pirogov
      • Nizhny Novgorod, Russia, 603950
        • Privolzhsky Research Medical University of Ministry of Health of Russian Federation
      • Yaroslavl, Russia, 150032
        • Yaroslavl Regional Children's Clinical Hospital
    • Delaware
      • Wilmington, Delaware, Stati Uniti, 19803
        • Nemours DuPont Hospital for Children
    • Georgia
      • Atlanta, Georgia, Stati Uniti, 30342
        • Children's Center for Digestive Health Care
    • Minnesota
      • Rochester, Minnesota, Stati Uniti, 55905
        • Mayo Clinic
    • New Jersey
      • Morristown, New Jersey, Stati Uniti, 07962
        • Morristown Memorial Hospital
    • North Carolina
      • Charlotte, North Carolina, Stati Uniti, 28207
        • Levine Childrens at Atrium Health
    • Ohio
      • Cleveland, Ohio, Stati Uniti, 44106
        • University Hospitals Cleveland Medical Center
    • Pennsylvania
      • Hershey, Pennsylvania, Stati Uniti, 17033
        • Penn State Hershey Children's Hospital
    • Texas
      • Fort Worth, Texas, Stati Uniti, 76104
        • Cook Childrens Medical Center
    • Virginia
      • Fairfax, Virginia, Stati Uniti, 22031
        • Pediatric Specialists Of Virginia
      • Budapest, Ungheria, 1083
        • Semmelweis Egyetem
      • Debrecen, Ungheria, 4032
        • Debreceni Egyetem Klinikai Kozpont
      • Miskolc, Ungheria, 3526
        • Borsod Abauj Zemplen Varmegyei Kozponti Korhaz es Egyetemi Oktato Korhaz
      • Nyíregyháza, Ungheria, 4400
        • Szabolcs Szatmár Bereg Vármegyei Oktatókórház
      • Szeged, Ungheria, 6720
        • Szegedi Tudományegyetem, Gyermekgyógyászati Klinika és Gyermekegészségügyi Centrum

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

Da 2 anni a 17 anni (Bambino)

Accetta volontari sani

No

Descrizione

Criterio di inclusione:

  • Avere la malattia di Crohn o la malattia di Crohn fistolizzante con colite attiva, ileite o ileocolite, confermata in qualsiasi momento nel passato da endoscopia e istologia
  • Deve avere una malattia di Crohn attiva da moderatamente a gravemente (come definita da un punteggio dell'indice di attività della malattia di Crohn pediatrico [PCDAI] al basale superiore a [>] 30); avere ileocolonoscopia con evidenza di malattia di Crohn attiva definita come presenza di ulcerazione (che è uguale al punteggio Simple Endoscopic Score per la malattia di Crohn [SES-CD] maggiore o uguale a [>=] 3) durante lo screening in questo studio. La procedura di ileocolonoscopia deve avvenire entro circa 3 settimane prima della somministrazione dell'intervento dello studio alla settimana 0 (periodo di induzione). Una video ileocolonoscopia registrata entro 3 mesi prima della visita della settimana 0 (periodo di induzione) può essere utilizzata in caso di nuovo screening di un partecipante che ha subito un'ileocolonscopia ma non ha superato lo screening iniziale per un altro motivo, caso per caso, dopo consultazione con lo sponsor. Se non è possibile valutare l'ulcerazione dovuta a stenosi o preparazione intestinale inadeguata, si può invece applicare almeno uno dei seguenti criteri: una proteina C-reattiva (CRP) anormale (> 0,3 milligrammi per decilitro [mg/dL] o 3,0 milligrammi per litro [mg/L] allo screening) o; calprotectina fecale di >= 250 milligrammi per chilogrammo [mg/kg] o >= 250 microgrammi per grammo [mcg/g] allo screening
  • Se riceve nutrizione enterale, deve essere stato a regime stabile per almeno 2 settimane prima della settimana 0 di induzione (settimana I-0)
  • Le donne in età fertile devono avere un test di gravidanza sulle urine altamente sensibile negativo allo screening e alla settimana I-0 prima della somministrazione dell'intervento dello studio

Criteri di esclusione:

  • Ha complicanze della malattia di Crohn come stenosi o stenosi sintomatiche, sindrome dell'intestino corto o qualsiasi altra manifestazione che potrebbe richiedere un intervento chirurgico, che potrebbe precludere l'uso del PCDAI per valutare la risposta alla terapia o potrebbe confondere la capacità di valutare la effetto del trattamento con ustekinumab
  • Avere una storia di infezione granulomatosa latente o attiva, istoplasmosi o coccidioidomicosi o aver avuto un'infezione da micobatteri non tubercolare prima dello screening
  • Presenza o anamnesi di qualsiasi tumore maligno inclusa la presenza o anamnesi di malattia linfoproliferativa compreso il linfoma, o segni e sintomi suggestivi di possibile malattia linfoproliferativa, come linfoadenopatia di dimensioni o localizzazione insolite (ad esempio, linfonodi nel triangolo posteriore del collo, sottoclavicolare, epitrocleare, o aree periaortiche) e gammopatia monoclonale di significato indeterminato, o epatomegalia o splenomegalia clinicamente significative
  • Avere una storia di insufficienza epatica o renale moderata o grave progressiva o incontrollata; o significativi disturbi cardiaci, vascolari, polmonari, gastrointestinali, endocrini, neurologici, ematologici, psichiatrici (compresi i suicidi) o metabolici
  • Ha ricevuto un intervento sperimentale che include eventuali vaccini sperimentali o ha utilizzato un dispositivo medico sperimentale invasivo entro 3 mesi prima della prima dose pianificata dell'intervento dello studio o è attualmente arruolato in uno studio sperimentale; la ricezione di un vaccino sperimentale per la malattia da coronavirus 2019 (COVID-19) non è un criterio di esclusione automatica

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Doppio

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Ustekinumab in aperto per via endovenosa (IV): periodo di induzione
Tutti i partecipanti riceveranno una singola somministrazione endovenosa di ustekinumab alla settimana 0 di induzione (I-0) in base alla superficie corporea (BSA) (milligrammi per metro quadrato [mg/m^2]) o dose di induzione a livelli di peso (milligrammi per chilogrammo [mg/kg]).
Ustekinumab verrà somministrato per via endovenosa nel periodo di induzione e per via sottocutanea nel periodo di mantenimento.
Sperimentale: Ustekinumab sottocutaneo (SC) ogni 8 settimane (q8w): periodo di mantenimento
I partecipanti riceveranno la somministrazione SC di ustekinumab ogni 8 settimane in base alla BSA (mg/m^2) o alla dose di induzione a livelli di peso (mg/kg) alle settimane di mantenimento (settimane M)-0, M-8, M-16, M-24 , M 32 e M-40 e placebo corrispondente alle settimane M-12 e M-36 per mantenere il cieco.
Ustekinumab verrà somministrato per via endovenosa nel periodo di induzione e per via sottocutanea nel periodo di mantenimento.
Il placebo corrispondente verrà somministrato come iniezione SC.
Sperimentale: Ustekinumab SC ogni 12 settimane (q12w): periodo di mantenimento
I partecipanti riceveranno la somministrazione sottocutanea di ustekinumab q12w in base alla BSA (mg/m^2) o alla dose di induzione a livelli di peso (mg/kg) alle settimane M-0, M-12, M-24, M-36 e il placebo corrispondente a Settimane M-8, M-16, M-32 e M-40 per mantenere i ciechi.
Ustekinumab verrà somministrato per via endovenosa nel periodo di induzione e per via sottocutanea nel periodo di mantenimento.
Il placebo corrispondente verrà somministrato come iniezione SC.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Global Outcome Measure: Percentage of Participants With Clinical Remission at Induction Week 8 (Week I-8)
Lasso di tempo: Induction Week 8 (Week I-8)
Clinical remission was defined as a Pediatric Crohn's Disease Activity Index (PCDAI) score <=10. The 11-item PCDAI covered five general disease activity domains: symptom history scores (3 items: abdominal pain, stool frequency, and general well-being); laboratory scores (3 items: hematocrit [HCT], erythrocyte sedimentation rate [ESR], Albumin); growth scores (2 items: weight and height); physical examination scores (2 items: abdomen and perirectal disease); and extraintestinal manifestations. The category of severity for each index item is assigned a score: 0=normal;5=mild abnormality; 10= severe abnormality. For hematocrit and erythrocyte SR, the maximum score =5. For albumin level, the maximum score = 10. All items were summed to derive the total score. The total PCDAI score ranged from 0 to 100, with higher scores indicating greater disease activity.
Induction Week 8 (Week I-8)
US-specific Outcome Measure: Percentage of Participants With Clinical Remission at Maintenance Week 44
Lasso di tempo: Maintenance Week 44 (Study Week 52)
Clinical remission was defined as a Pediatric Crohn's Disease Activity Index (PCDAI) score <=10. The 11-item PCDAI covered five general disease activity domains: symptom history scores (3 items: abdominal pain, stool frequency, and general well-being); laboratory scores (3 items: HCT, ESR, Albumin); growth scores (2 items: weight and height); physical examination scores (2 items: abdomen and perirectal disease); and extraintestinal manifestations. The category of severity for each index item was assigned a score: 0=normal;5=mild abnormality; 10= severe abnormality. For hematocrit and erythrocyte SR, the maximum score= 5. For albumin level, the maximum score= 10. All items were summed to derive the total score. The total PCDAI score ranged from 0 to 100, with higher scores indicating greater disease activity.
Maintenance Week 44 (Study Week 52)
Global and US-specific Outcome Measures: Number of Participants With Treatment-emergent Adverse Events (TEAEs)
Lasso di tempo: Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 44 (Study Week 52)
Number of participants with TEAEs were reported. An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE did not necessarily have a causal relationship with the intervention. TEAEs were defined as AEs occurring at or after the initial administration of the study intervention.
Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 44 (Study Week 52)
Global and US-specific Outcome Measures: Number of Participants With Treatment-emergent Serious Adverse Events (TESAEs)
Lasso di tempo: Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 44 (Study Week 52)
Number of participants with TESAEs was reported. An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE did not necessarily have a causal relationship with the intervention. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; or congenital anomaly. TESAEs were defined as any SAE occurring at or after the initial administration of the study intervention.
Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 44 (Study Week 52)
Global and US-specific Outcome Measures: Number of Participants With AEs Leading to Discontinuation of Study Intervention
Lasso di tempo: Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 40 (Study Week 48)
Number of participants with AEs leading to discontinuation of study intervention were reported.
Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 40 (Study Week 48)
Global and US-specific Outcome Measures: Number of Participants With AEs of Special Interest (AESI)
Lasso di tempo: Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 44 (Study Week 52)
An AE was any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE did not necessarily have a causal relationship with the intervention. AESI were defined as any newly identified malignancy, or case of active TB, or opportunistic infection occurring after the first administration of study intervention.
Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 44 (Study Week 52)
Global and US-specific Outcome Measures: Number of Participants With Abnormalities in Clinical Laboratory Parameters: Hematology
Lasso di tempo: Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 44 (Study Week 52)
Number of participants with abnormalities in clinical laboratory parameters (hematology) were reported. It included hemoglobin (Hb). Grades 0-4 were based on the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE), where Grade 0 was normal, Grade 1 was mild, Grade 2 was moderate, Grade 3 was severe or medically significant but not immediately life-threatening, and Grade 4 was life-threatening consequences. Higher grades showed more severe abnormalities. Only abnormalities where atleast one participant had data are reported. Inc = increased, Dec= decreased.
Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 44 (Study Week 52)
Global and US-specific Outcome Measures: Number of Participants With Abnormalities in Clinical Laboratory Parameters: Chemistry
Lasso di tempo: Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 44 (Study Week 52)
Number of participants with abnormalities in clinical laboratory parameters were reported. It included chemistry measures: alanine aminotransferase (ALT), aspartate aminotransferase (AST),blood bilirubin (BB). Grades 0-4 were based on NCI-CTCAE version 5.0, where Grade 0 was Normal, Grade 1 was mild, Grade 2 was moderate, Grade 3 was severe or medically significant but not immediately life-threatening, and Grade 4 was life-threatening consequences. Higher grades showed more severe abnormalities. Only abnormalities where at least one participant had data are reported. Inc = increased, Dec= decreased.
Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 44 (Study Week 52)
Global and US-specific Outcome Measures: Number of Participants With Reactions Temporally Associated With Intravenous (IV) Infusion (Induction Period) and Subcutaneous (SC) Injection-Site Reactions (Maintenance Period)
Lasso di tempo: Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 44 (Study Week 52)
Number of participants with reactions temporally associated with intravenous (IV) infusion (Induction Period) and subcutaneous (SC) Injection-Site Reactions (Maintenance Period) were reported.
Induction Period: From induction Week 0 up to induction Week 8; Maintenance Period: From Maintenance Week 0 (Study Week 8) up to Maintenance Week 44 (Study Week 52)
Global and US-specific Outcome Measures: Serum Ustekinumab Concentrations
Lasso di tempo: Induction Period: Week 0 (Pre-infusion), Week I-0 (1-hour post infusion), Week I-3, Week I-6, and Week I-8; Maintenance Period: Week M-4, Week M-8, Week M-12, Week M-16, Week M-24, Week M-32, Week M-36 and Week M-44
Serum ustekinumab concentrations were reported.
Induction Period: Week 0 (Pre-infusion), Week I-0 (1-hour post infusion), Week I-3, Week I-6, and Week I-8; Maintenance Period: Week M-4, Week M-8, Week M-12, Week M-16, Week M-24, Week M-32, Week M-36 and Week M-44

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Global Outcome Measure: Percentage of Participants With Clinical Remission at Induction Week 6 as Assessed by Short Pediatric Crohn's Disease Activity Index (sPCDAI)
Lasso di tempo: Induction Week 6 (Week I-6)
Clinical remission was defined as a short Pediatric Crohn's Disease Activity Index (sPCDAI) score <=10. The sPCDAI was composed of six components: abdominal pain, stool frequency, patient general well-being, body weight, abdominal examination (abdominal mass and tenderness), and extraintestinal manifestations. Each component was assigned a score of 0, 5, 10, or 20, depending on the severity of findings, with higher scores indicating greater disease activity, while lower scores (closer to 0) reflected clinical remission or minimal disease activity. Individual component scores were summed to derive the total sPCDAI score, which ranged from 0 to 90. Higher score indicate greater severity. The sPCDAI score was calculated only when >=3 of the 6 components were available.
Induction Week 6 (Week I-6)
Global Outcome Measure: Percentage of Participants With Clinical Response at Induction Week 8
Lasso di tempo: Induction Week 8
Assessment of response in children with Crohn's disease was evaluated using the PCDAI. Clinical response was defined as a reduction from baseline of >=12.5 points in the PCDAI score, calculated by summing weighted scores from 11 items across five domains: symptom history (abdominal pain, stool frequency, and general well-being); laboratory scores (hematocrit, erythrocyte sedimentation rate, and albumin); growth scores (weight and height); physical examination scores (abdominal and perirectal disease); and extraintestinal manifestations. Each index item was assigned a severity score of 0 (normal), 5 (mild abnormality), or 10 (severe abnormality). For HCT and ESR, maximum score was 5, and for albumin level, maximum score was 10. The total PCDAI score ranged from 0 to 100, with higher scores indicating greater disease activity. Lower PCDAI scores reflected lower disease activity, with a resulting score of <=30 on the 0-100 scale.
Induction Week 8
Global and US-specific Outcome Measures: Percentage of Participants With Clinical Response at Induction Week 6 as Assessed by sPCDAI
Lasso di tempo: Induction Week 6
sPCDAI clinical response was defined as reduction from baseline in the sPCDAI score of >=10. The 6-item sPCDAI score ranges from 0 (no disease activity) to 90 (severe disease activity),calculated by summing weighted scores for abdominal pain, stool frequency, general well-being, body weight, abdominal exam, and extraintestinal manifestations. Each component was assigned a score of 0, 5, 10, or 20, depending on the severity of findings, with higher scores indicating greater disease activity, while lower scores (closer to 0) reflected minimal disease activity. Individual component scores were summed to derive the total sPCDAI score, which ranged from 0 to 90. Higher score indicate greater severity. The sPCDAI score was only calculated when >=3 of the 6 components were available.
Induction Week 6
Global Outcome Measure: Percentage of Participants With Endoscopic Response at Maintenance Week 8 as Assessed by Simplified Endoscopic Score-Crohn's Disease (SES-CD)
Lasso di tempo: Maintenance Period Week 8 (Study Week 16)
Endoscopic response was assessed using the Simplified Endoscopic Activity Score for Crohn's Disease (SES-CD), a validated endoscopic scoring system based on four components: size of ulcers, extent of ulcerated surface, extent of affected surface, and presence of narrowing. Each component was scored from 0 to 3 across five intestinal sections: ileum, right colon, transverse colon, left (descending and sigmoid) colon, and rectum. Component scores were summed across all sections to derive a total SES-CD score ranging from 0 to 56, with higher scores indicating greater endoscopic disease severity. Endoscopic response was defined as a >=50% reduction from baseline in SES-CD score or achievement of an SES-CD score <=2 in participants with a baseline SES-CD score >=3.
Maintenance Period Week 8 (Study Week 16)
Global Outcome Measure: Percentage of Participants With Clinical Response at Maintenance Week 8
Lasso di tempo: Maintenance Week 8 (Study Week 16)
Clinical response was defined as a reduction from baseline of >=12.5 points in PCDAI score, calculated by summing weighted scores from 11 items across five domains: symptom history(abdominal pain, stool frequency, and general well-being); laboratory scores (hematocrit, erythrocyte sedimentation rate, and albumin); growth scores(weight and height); physical examination scores(abdominal and perirectal disease); extraintestinal manifestations. Each index item was assigned a severity score of 0(normal), 5(mild abnormality), or 10(severe abnormality). For HCT and ESR, maximum score was 5, for albumin level, maximum score was 10. Total PCDAI score ranged from 0 to 100, with higher scores indicating greater disease activity. Lower PCDAI scores reflected lower disease activity, with resulting score of <=30 on 0-100 scale.
Maintenance Week 8 (Study Week 16)
Global and US-specific Outcome Measures: Percentage of Participants With Endoscopic Response at Maintenance Week 44 as Assessed by SES-CD
Lasso di tempo: Maintenance Week 44 (Study Week 52)
Endoscopic response was assessed using the Simplified Endoscopic Activity Score for Crohn's Disease (SES-CD), a validated endoscopic scoring system based on four components: size of ulcers, extent of ulcerated surface, extent of affected surface, and presence of narrowing. Each component was scored from 0 to 3 across five intestinal sections: ileum, right colon, transverse colon, left (descending and sigmoid) colon, and rectum. Component scores were summed across all sections to derive a total SES-CD score ranging from 0 to 56, with higher scores indicating greater endoscopic disease severity. Endoscopic response was defined as a >=50% reduction from baseline in SES-CD score or achievement of an SES-CD score <=2 in participants with a baseline SES-CD score >=3.
Maintenance Week 44 (Study Week 52)
US-specific Outcome Measure: Percentage of Participants With Clinical Response at Maintenance Week 44
Lasso di tempo: Maintenance Week 44 (Study Week 52)
Clinical response was defined as a reduction from baseline of >=12.5 points in PCDAI score, calculated by summing weighted scores from 11 items across five domains: symptom history(abdominal pain, stool frequency, and general well-being); laboratory scores (hematocrit, erythrocyte sedimentation rate, and albumin); growth scores(weight and height); physical examination scores(abdominal and perirectal disease); extraintestinal manifestations. Each index item was assigned a severity score of 0(normal), 5(mild abnormality), or 10(severe abnormality). For HCT and ESR, maximum score was 5, for albumin level, maximum score was 10. Total PCDAI score ranged from 0 to 100, with higher scores indicating greater disease activity. Lower PCDAI scores reflected lower disease activity, with resulting score of <=30 on 0-100 scale.
Maintenance Week 44 (Study Week 52)
US-specific Outcome Measure: Percentage of Participants With Corticosteroid-free Clinical Remission at Maintenance Week 44
Lasso di tempo: Maintenance Period Week 44 (Study Week 52)
Corticosteroid-free remission was defined as PCDAI score of <=10 points and not receiving corticosteroids for at least 90 days prior to Week M-44. The 11-item PCDAI covered five general disease activity domains: symptom history scores (3 items: abdominal pain, stool frequency; and general well-being); laboratory scores (3 items: HCT, ESR, Albumin); growth scores (2 items: weight and height), physical examination scores (2 items: abdomen and perirectal disease), and extraintestinal manifestations. The category of severity for each index item was assigned a score: 0=normal;5=mild abnormality; 10= severe abnormality. For hematocrit and erythrocyte SR, the maximum score= 5. For albumin level, the maximum score= 10. All items were summed to derive the total score. The total PCDAI score ranged from 0 to 100, with higher scores indicating greater disease activity.
Maintenance Period Week 44 (Study Week 52)
Global Outcome Measure: Percentage of Participants With Clinical Remission at Maintenance Week 44 Who Had Clinical Remission at Induction Week 8
Lasso di tempo: Maintenance Week 44 (Study Week 52)
Clinical remission was defined as Pediatric Crohn's Disease Activity Index (PCDAI) score <=10. The 11-item PCDAI covered five general disease activity domains: symptom history scores (3 items: abdominal pain, stool frequency; and general well-being); laboratory scores (3 items: HCT, ESR, Albumin); growth scores (2 items: weight and height), physical examination scores (2 items: abdomen and perirectal disease), and extraintestinal manifestations. The category of severity for each index item was assigned a score: 0=normal;5=mild abnormality; 10= severe abnormality. For hematocrit and erythrocyte SR, the maximum score= 5. For albumin level, the maximum score= 10. All items were summed to derive the total score. The total PCDAI score ranged from 0 to 100, with higher scores indicating greater disease activity.
Maintenance Week 44 (Study Week 52)

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Investigatori

  • Direttore dello studio: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC

Pubblicazioni e link utili

La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

6 aprile 2021

Completamento primario (Effettivo)

28 novembre 2024

Completamento dello studio (Effettivo)

3 marzo 2025

Date di iscrizione allo studio

Primo inviato

14 dicembre 2020

Primo inviato che soddisfa i criteri di controllo qualità

14 dicembre 2020

Primo Inserito (Effettivo)

17 dicembre 2020

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

30 luglio 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

2 luglio 2026

Ultimo verificato

1 luglio 2026

Maggiori informazioni

Termini relativi a questo studio

Parole chiave

Altri numeri di identificazione dello studio

  • CR108864
  • 2019-004225-24 (Numero EudraCT)
  • CNTO1275CRD3004 (Altro identificatore: Janssen Research & Development, LLC)
  • 2023-504978-38-00 (Identificatore di registro: EUCT number)

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

SÌ

Descrizione del piano IPD

La politica di condivisione dei dati delle società farmaceutiche Janssen di Johnson & Johnson è disponibile all'indirizzo www.janssen.com/clinical-trials/transparency. Come indicato su questo sito, le richieste di accesso ai dati dello studio possono essere inviate tramite il sito del progetto Yale Open Data Access (YODA) all'indirizzo yoda.yale.edu

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

Sì

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi